Josh Lehrer
Chief executive: LENZ Therapeutics, Inc. (before 2014 to 21 Aug 2023)
5commitments announced
5with a clear outcome
0met on time
–rate shown after 15 outcomes
Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: LENZ Therapeutics, Inc. filing.
Commitments announced under Josh Lehrer
| LENZ Therapeutics, Inc.announced 11 Aug 2022 | Report initial proof-of-concept data for nula-cel | Not met30 Jun 2023 |
| LENZ Therapeutics, Inc.announced 21 Mar 2022 | Submit an IND for the GPH102 program due after leader left | Withdrawn30 Jun 2024 |
| LENZ Therapeutics, Inc.announced 17 Nov 2021 | Treat the first patient with GPH101 | Late30 Jun 2022 |
| LENZ Therapeutics, Inc.announced 10 Nov 2021 | Enroll the first patient in the CEDAR clinical trial | Not met31 Dec 2021 |
| LENZ Therapeutics, Inc.announced 10 Nov 2021 | Report initial proof-of-concept data for the CEDAR clinical trial | Not met31 Dec 2022 |
Is this record wrong, or are you Josh Lehrer? Add a statement or ask for a correction.